Navigation Links
Cardiome To Release Third Quarter Results
Date:11/12/2007

on of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at http://www.sec.gov and the Canadian securities regulatory authorities at http://www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by t
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
5. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
6. First New York/New Jersey Health Care Report Card Released
7. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
8. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
9. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
10. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
11. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ench . , An innovative treatment for HIV pat... researchers has passed its first clinical trial w...herapy customized for each individual patient, and... Institute of the MUHC in collaboration with Dr. R...vaccine made for the individual patient an "haute...
(Date:11/25/2009)...ess for patients with liver lesions, researchers f...ws) -- Adding the drug cetuximab to neoadjuvant ch... successful surgery in colorectal cancer patients ...arch suggests. , , Tumors spread to other part...olorectal cancer. Most commonly, the cancer spread...
(Date:11/25/2009)...pport for recent enforcement actions against rogue...ion of Chain Drug Stores (NACDS) submitted a lette...letter expresses the Association’s concern a...gn, that are engaged in a pattern of illegal activ...escription medications. , ...
(Date:11/25/2009)...-Reportlinker.comannouncesthatanewmarketresearchre...rAnti-ageingFoods(2ndEdition) ,, http://www....ng-Foods-(2nd-Edition ).html ,, Theglobalfuncti...owthoutstrippingthatofconventionalfoods,andproduct...ive,sstrictapproachtohealthclaimshoweverwillclearl...
(Date:11/25/2009)...Flexibility,AllowingCompanytoAccessCapitalatitsDis...stCall/-LabopharmInc.(TSX:DDS;NASDAQ: DDSS )todaya...agreement(SEDA)withYAGlobalMasterSPVLtd.,afundmana...ment,YAhascommittedtoprovideupto$25millionofcapita...hroughthepurchaseofnewlyissuedLabopharmcommonshare...
Breaking Medicine News(10 mins):Health News:Tailor-made HIV/AIDS treatment closer to reality 2Health News:Cetuximab Helps Treat Colorectal Cancer 2Health News:NACDS Supports FDA Enforcement Against Rogue Internet Pharmacy Websites 2Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 2Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 3Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 4Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 5Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 6Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 3
...lysis, the use of dialysis filters coated with vit...mmon problem of anemia, reports a paper presented ...nual Meeting and Scientific Exposition in San Dieg... were switched from "regular" dialysis filters to ...
...retakers sent letters to city, state and federal a...osal procedures were not stringent //enough in tre...iseases such as mad cow and chronic wasting diseas...e at length. The eight-person panel investigated t...
...tion about the risks of nanotechnology in society,...owerful potential according //to 14 top internatio...ovember 16th issue of the journal Nature. The pape...ach its full promise. The paper's lead author...
...worship-with 1,000 pyres began Friday here to ward...Amid chanting of Vedic hymns by Hindu priests from...on their heads, the ritual was performed with the ...ngha, was to ward off dengue, malaria and other di...
...nalities may face risk of developing coronary hear... led by Edward Suarez at Duke University studied 2...during the Vietnam War. The men got heart c...on of health magazine WebMD. Each of these ...
...s information available on the internet is causing...g to a health watchdog. // The NHS Quality Imp... available on the web have been increasing the dan...alth watch dog for doctors in Scotland on the best...
Other Medicine News:Health News:Vitamin E-Coated Dialysis Filters Help Fight Anemia in Hemodialysis Patients 2Health News:Complaints Against US Federal lab Over-ruled by Panel 2Health News:Fear of Possible Harm Hinder Nanotech Development 2Health News:Internet Health Advice Causing More Harm than Good 2
(Date:11/24/2009)...irstCall/--AnadysPharmaceuticals,Inc.(Nasdaq: ANDS...perJaffrayHealthcareConferenceonTuesday,December1,...gheldatTheNewYorkPalaceHotel.SteveWorland,Ph.D.,Pr...eanoverviewofAnadysanditsclinicaldevelopmentprogra...willbesimultaneouslywebcastandcanbeaccessedontheIn...
(Date:11/24/2009)...wire/--ZargisMedicalCorp.,asubsidiaryofSpeedusCorp...search(NYSE: SI ),todayannouncedthatitsZargisCardi...fCBS, TheEarlyShow duringasegmentinwhichMarkJannot...inningproductsfromthepublication,s2009"BestofWhat,...elevisionmorningnewstalkshowbroadcastbyCBSfromNewY...
(Date:11/24/2009)...-USNewswire/--America,spharmaceuticalresearchandbi...estotreatorpreventHIV/AIDSandrelatedconditions,acc...ResearchandManufacturersofAmerica(PhRMA).December1...renesscampaignthatoriginatedatthe1988WorldSummitof..., "Wearegreatlyencouragedbythesecriticallyimport...
Breaking Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Top 10 Ways to Prevent or Delay Alzheimer 26apos 3Bs 60811 1Top 10 Ways to Prevent or Delay Alzheimer 26apos 3Bs 60811 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections 28ABSSSI 29 6040 1Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections 28ABSSSI 29 6040 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections 28ABSSSI 29 6040 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections 28ABSSSI 29 6040 4ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 1ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 2ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 3
...wswire/ -- Mersana, a,cancer therapeutics company,...es with its lead product candidate, XMT-1001, will...eting of the,American Association of Cancer Resear...s, CA. Full text of the abstracts can be,viewed on...f=,"http://www.aacr.org/">http://www.AACR.org . , ...
...e Oncology Compounds at the,American Association f...l., April 13, 2007 /PRNewswire-FirstCall/ -- For,d...hat target,cancer. Researchers now know that cance...y require new blood vessels to deliver oxygen,and ...,(proliferation), they travel throughout the body ...
Other Medicine Technology:Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 3Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 4
...nsfers depurinated DNA and RNA from agarose gels t...es ,Increases speed and efficiency of transfer by ...of an integrated system allowing electrophoresis, ... hours, versus 29 hours required for conventional ...
...nsfers depurinated DNA and RNA from agarose gels t...es ,Increases speed and efficiency of transfer by ...of an integrated system allowing electrophoresis, ... hours, versus 29 hours required for conventional ...
PosiBlot 30-30 Pads
Liquid Trap
Medicine Products: